Summary by Moomoo AI
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 50,000 shares of the company's common stock. The transaction, scheduled for January 29, 2024, is valued at approximately $3,025,570. The shares to be sold were acquired on the same day through the exercise of stock options, with the securities originating from the issuer and purchased with cash. This sale follows a previous transaction in the past three months where Kulkarni sold 20,000 shares, garnering total gross proceeds of $1,250,056.